CURATIVE共识第5部分:小动物抗血栓药物停用
该共识系统评价了小动物抗血小板或抗凝药物永久或临时停用的时机与机制,采用标准化文献系统评价、证据等级与质量分级,并通过Delphi式调查形成共识。共涉及两个探究方向:侵入性操作(如手术)前临时停用和完全停用抗凝药物的决策,以及肝素停用的最佳方法。结论推荐高血栓风险患者侵入性操作期间继续抗凝,低至中风险者可考虑停用;血栓原因已解除者不推荐无限期抗凝,原因未知或不可治疗者应无限期继续;普通肝素应缓慢减量而非突然停用。
要点
- 高血栓风险且正在接受抗凝治疗的患者,推荐在侵入性操作期间继续抗凝治疗。
- 低至中度血栓风险的患者,考虑停用抗凝治疗是合理的。
- 血栓原因已解除的患者,不推荐无限期抗凝治疗。
- 血栓原因未知或不可治疗的患者,应无限期继续抗凝治疗。
- 普通肝素治疗应缓慢减量,而非突然停用。
适用人群与场景
- 接受抗血小板或抗凝药物、需要临时停用该治疗以进行侵入性操作(如手术)的小动物患者。
- 需要决策是否完全停用抗凝药物的小动物患者。
处置流程与药物剂量
- 高血栓风险且正在接受抗凝治疗的患者,推荐在侵入性操作期间继续抗凝治疗。
- 低至中度血栓风险的患者,考虑停用抗凝治疗是合理的。
- 血栓原因已解除的患者,不推荐无限期抗凝治疗。
- 血栓原因未知或不可治疗的患者,应无限期继续抗凝治疗。
- 普通肝素治疗应缓慢减量,而非突然停用。
研究设计与关键结果
- 该共识通过标准化系统文献评价、证据等级与质量分级(差、一般、好),并经Delphi式调查形成共识结论。
- 文献检索数据库包括Medline(通过PubMed)和CAB摘要。
- 两个探究方向:侵入性操作前临时停用抗血小板或抗凝药物的方法,以及完全停用抗凝药物的决策。
- 还涉及肝素停用的最适方法。
证据类型、等级与局限
- 证据类型:指南/共识(CURATIVE共识),基于系统文献评价与Delphi式调查形成。
- 局限:原文未报告局限性
对床旁实践的改变
- 对高血栓风险患者,侵入性操作期间不应常规停用抗凝药物。
- 对低至中度血栓风险患者,可考虑停用抗凝药物。
- 血栓原因已解除者不应无限期抗凝,原因未知或不可治疗者应无限期抗凝。
- 普通肝素应缓慢减量而非突然停用。
指南或共识出处
- CURATIVE共识第5部分:小动物抗血栓药物停用(Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care, Domain 5)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To systematically evaluate the evidence supporting the timing and mechanisms of permanent or temporary discontinuation of antiplatelet or anticoagulant medications in small animals DESIGN: Standardized, systematic evaluation of the literature, categorization of relevant articles according to level of evidence and quality (poor, fair, or good), and development of consensus on conclusions via a Delphi-style survey for application of the concepts to clinical practice.
SETTINGS: Academic and referral veterinary medical centers.
RESULTS: Databases searched included Medline via PubMed and CAB abstracts. Two specific courses of inquiry were pursued, one focused on appropriate approaches to use for small animal patients receiving antiplatelet or anticoagulant drugs and requiring temporary discontinuation of this therapy for the purposes of invasive procedures (eg, surgery), and the other aimed at decision-making for the complete discontinuation of anticoagulant medications. In addition, the most appropriate methodology for discontinuation of heparins was addressed.
CONCLUSIONS: To better define specific patient groups, a risk stratification characterization was developed. It is recommended to continue anticoagulant therapy through invasive procedures in patients at high risk for thrombosis that are receiving anticoagulant therapy, while consideration for discontinuation in patients with low to moderate risk of thrombosis is reasonable. In patients with thrombosis in whom the underlying cause for thrombosis has resolved, indefinite treatment with anticoagulant medication is not recommended. If the underlying cause is unknown or untreatable, anticoagulant medication should be continued indefinitely. Unfractionated heparin therapy should be slowly tapered rather than discontinued abruptly.
参考来源
- Brainard BM, Buriko Y, Good J, et al. Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care (CURATIVE): Domain 5-Discontinuation of anticoagulant therapy in small animals. J Vet Emerg Crit Care (San Antonio). 2019. PMID: 30654425. doi:10.1111/vec.12796
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。